細胞核受容体アゴニストのパイプライン・インサイト2018

DelveInsightが発行した調査報告書(DIMR2016524)
◆英語タイトル:Nuclear Receptor Agonists -Pipeline Insights, 2018
◆商品コード:DIMR2016524
◆発行会社(リサーチ会社):DelveInsight
◆発行日:2018年10月
◆ページ数:約60
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:製薬
◆販売価格オプション(消費税別)
Single User(1名使用)USD1,250 ⇒換算¥141,250見積依頼/購入/質問フォーム
Site Price(同一国内共有可)USD2,500 ⇒換算¥282,500見積依頼/購入/質問フォーム
Enterprise Price(複数国内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はDelveInsight社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。DelveInsight社の概要及び新刊レポートはこちらでご確認いただけます。

本調査レポートでは、世界における細胞核受容体アゴニストのパイプライン動向について調査・分析し、以下の構成でお届けいたします。

・細胞核受容体アゴニストの概要
・細胞核受容体アゴニストのパイプライン概要
・企業別開発中の細胞核受容体アゴニスト
・後期治験段階の薬剤(Filed & Phase III):比較分析
・中期治験段階の薬剤(Phase II):比較分析
・初期治験段階の薬剤(Phase I & IND Filed):比較分析
・薬剤候補のプロファイル
・細胞核受容体アゴニストの評価
  - 単剤治療薬別評価
  - 併用治療薬別評価
  - 投与経路別評価
  - 分子種類別評価
・開発が中止された薬剤リスト
・開発休止中の薬剤リスト
・細胞核受容体アゴニスト開発に取り組んでいる企業リスト
・図表一覧
【レポートの概要】

SUMMARY
DelveInsight’s, “Nuclear Receptor Agonists-Pipeline Insights, 2018”, report provides in depth insights on the pipeline drugs and their development activities around the Nuclear Receptor Agonists. The DelveInsight’s Report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. Report covers the product clinical trials information and other development activities including technology, licensing, collaborations, acquisitions, fundings, patent and USFDA & EMA designations details. DelveInsight’s Report also provides detailed information on the discontinued and dormant drugs that have gone inactive over the years for Nuclear Receptor Agonists. DelveInsight’s Report also assesses the Nuclear Receptor Agonists therapeutics by Monotherapy, Combination products, Molecule type and Route of Administration.

Please note: This report requires certain updates. We have all the information available but require 3 business days to complete the process and ensure it is as up-to-date as possible. Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated indication.


Scope
• The report provides competitive pipeline landscape of Nuclear Receptor Agonists
• The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information
• Coverage of the Nuclear Receptor Agonists pipeline on the basis of target, MOA, route of administration, technology involved and molecule type
• The report reviews key players involved in the therapeutics development for Nuclear Receptor Agonists and also provide company profiling
• The report also gives the information of dormant and discontinued pipeline projects
• Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages
• Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type


【レポートの目次】

Table of Contents
• Nuclear Receptor Agonists Overview
• Nuclear Receptor Agonists Disease Associated
• Nuclear Receptor Agonists Pipeline Therapeutics
• Nuclear Receptor Agonists Therapeutics under Development by Companies
• Nuclear Receptor Agonists Filed and Phase III Products
• Comparative Analysis
• Nuclear Receptor Agonists Phase II Products
• Comparative Analysis
• Nuclear Receptor Agonists Phase I and IND Filed Products
• Comparative Analysis
• Nuclear Receptor Agonists Discovery and Pre-Clinical Stage Products
• Comparative Analysis
• Drug Candidate Profiles
• Nuclear Receptor Agonists – Therapeutics Assessment
• Assessment by Monotherapy Products
• Assessment by Combination Products
• Assessment by Route of Administration
• Assessment by Molecule Type
• Nuclear Receptor Agonists – Discontinued Products
• Nuclear Receptor Agonists – Dormant Products
• Companies Involved in Therapeutics Development for Nuclear Receptor Agonists
• Appendix
• Methodology
• Contact Us
• Disclaimer

List of Tables
• Number of Products under Development for Nuclear Receptor Agonists by Therapy Area, 2018
• Number of Products under Development for Nuclear Receptor Agonists, 2018
• Number of Products under Development by Companies
• Comparative Analysis by Filed and Phase III Products, 2018
• Comparative Analysis Phase II Products, 2018
• Comparative Analysis Phase I and IND Filed Products, 2018
• Comparative Analysis Discovery and Pre-Clinical Stage Products, 2018
• Drug Candidates Profiles
• Nuclear Receptor Agonists Assessment by Monotherapy Products
• Nuclear Receptor Agonists Assessment by Combination Products
• Nuclear Receptor Agonists Assessment by Route of Administration
• Nuclear Receptor Agonists Assessment by Stage and Route of Administration
• Nuclear Receptor Agonists Assessment by Molecule Type
• Nuclear Receptor Agonists Assessment by Stage and Molecule Type
• Nuclear Receptor Agonists Therapeutics – Discontinued Products
• Nuclear Receptor Agonists Therapeutics – Dormant Products
• Products under Development by Companies, 2018


List of Figures
• Number of Products under Development for Nuclear Receptor Agonists by Therapy Area, 2018
• Number of Products under Development for Nuclear Receptor Agonists, 2018
• Filed and Phase III Products, 2018
• Phase II Products, 2018
• Phase I and IND Filed Products, 2018
• Discovery and Pre-Clinical Stage Products, 2018
• Nuclear Receptor Agonists Assessment by Monotherapy Products
• Nuclear Receptor Agonists Assessment by Combination Products
• Nuclear Receptor Agonists Assessment by Route of Administration
• Nuclear Receptor Agonists Assessment by Stage and Route of Administration
• Nuclear Receptor Agonists Assessment by Molecule Type
• Nuclear Receptor Agonists Assessment by Stage and Molecule Type


【レポートのキーワード】

細胞核受容体アゴニスト、医薬品、製薬、研究開発、パイプライン、治療、治験

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 細胞核受容体アゴニストのパイプライン・インサイト2018(Nuclear Receptor Agonists -Pipeline Insights, 2018)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆